Anticancer response to disulfiram may be enhanced by co-treatment with MEK inhibitor or oxaliplatin: modulation by tetrathiomolybdate, KRAS/BRAF mutations and c-MYC/p53 status

Ammonium tetrathiomolybdate (TTM) and disulfiram (DSF) are copper (Cu) chelators in cancer clinical trials partly because Cu chelation: a) restricts the activity of Cu-binding MEK1/2 enzymes which drive tumourigenesis by KRAS or BRAF oncogenic mutations and b) enhances uptake of oxaliplatin (OxPt),...

Descripción completa

Detalles Bibliográficos
Autores principales: Calderon-Aparicio, Ali, Cornejo, Alejandro, Orue, Andrea, Rieber, Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369974/
https://www.ncbi.nlm.nih.gov/pubmed/30792807
http://dx.doi.org/10.3332/ecancer.2019.890

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369974/
https://www.ncbi.nlm.nih.gov/pubmed/30792807
http://dx.doi.org/10.3332/ecancer.2019.890

Ejemplares similares